Clinical trials in Manresa

62 clinical trials in Manresa, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Manresa at a glance

clinical trials

Research sites0

Quick filters

62 trials in Manresa

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

Spain

Participants:18–64 years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Sargramostim
Sponsor:Greenwich LifeSciences Inc.

Contact Research Centre

Non-small cell lung cancer stage IV

Recruiting

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Eikon Therapeutics Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo

A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Infliximab
Sponsor:AstraZeneca AB

Contact Research Centre

Conjunctivitis allergic+1

Recruiting

Study of the efficacy and safety of depigmented polymerized grass pollen extracts for patients with allergic rhinitis and controlled asthma.

Investigational

Study of the efficacy and safety of depigmented polymerized grass pollen extracts for patients with allergic rhinitis and controlled asthma.

Investigational

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dactylis Glomerata Pollen Extract
Sponsor:LETI Pharma S.L.U.

Contact Research Centre

Neoplasm malignant

Recruiting

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Medilink Therapeutics (Suzhou) Co. Ltd.

Contact Research Centre

Mite allergy

Recruiting

A study testing dust mite allergy extracts from Dermatophagoides pteronyssinus and Dermatophagoides farinae for patients with allergic rhinoconjunctivitis with or without controlled asthma

Registered drug

A study testing dust mite allergy extracts from Dermatophagoides pteronyssinus and Dermatophagoides farinae for patients with allergic rhinoconjunctivitis with or without controlled asthma

Registered drug

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Budesonide
Sponsor:LETI Pharma S.L.U.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Quizartinib Dihydrochloride
Sponsor:Fundacion PETHEMA

Contact Research Centre

Major depression

Recruiting

A study testing intranasal esketamine compared to midazolam for rapidly reducing symptoms of major depressive disorder in adolescents with suicidal thoughts or behavior

Registered drug

A study testing intranasal esketamine compared to midazolam for rapidly reducing symptoms of major depressive disorder in adolescents with suicidal thoughts or behavior

Registered drug

Spain

Participants:0–17 years
Substances:Esketamine
Sponsor:Janssen Cilag International

Contact Research Centre

Small cell lung cancer limited stage

Recruiting

Study of tarlatamab maintenance treatment after chemotherapy and radiation therapy in patients with limited stage small cell lung cancer who cannot receive both treatments together

InvestigationalNo placebo

Study of tarlatamab maintenance treatment after chemotherapy and radiation therapy in patients with limited stage small cell lung cancer who cannot receive both treatments together

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:Fundacion GECP

Contact Research Centre

Bacterial prostatitis

Recruiting

Study on the Effectiveness of Fosfomycin, Cefixime, and Ciprofloxacin in Treating Acute Bacterial Prostatitis in Adult Men

Registered drugNo placebo

Study on the Effectiveness of Fosfomycin, Cefixime, and Ciprofloxacin in Treating Acute Bacterial Prostatitis in Adult Men

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cefixime
Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Contact Research Centre

Fallopian tube cancer+5

Recruiting

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

Registered drugNo placebo

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V.

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Manresa

What the registry says about research in the country

01 Oncology - Breast Cancer Research

Extensive clinical trials focusing on triple-negative breast cancer and HER2-positive breast cancer treatments, evaluating innovative therapies including atezolizumab, abemaciclib, and elacestrant.

Early-stage breast cancer treatments
Hormone receptor-positive therapy
Neoadjuvant chemotherapy approaches

Studies aim to improve survival rates and treatment outcomes through personalized therapeutic approaches.

02 Urological Oncology

Groundbreaking research in urothelial cancer and prostate cancer treatments, investigating novel combinations of immunotherapy and targeted therapies.

Metastatic castration-resistant prostate cancer
Bladder cancer interventions
Advanced urothelial carcinoma

Focus on improving progression-free survival through innovative treatment combinations.

03 Respiratory Medicine

Advanced research in severe asthma and lung cancer treatments, exploring new therapeutic approaches including immunotherapy combinations.

Non-small cell lung cancer therapy
Eosinophilic asthma management
Targeted respiratory interventions

Innovative approaches combining surgery, chemotherapy, and immunotherapy for optimal patient outcomes.

Back to Spain All countries